# Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

Study · id `cardio:ct-nct02489539` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02489539](<https://clinicaltrials.gov/study/NCT02489539>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02489539

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 175 participants.

## Technical summary

Registry record NCT02489539. Non-randomized; no masking; primary purpose treatment. Start 2017-12-19 (actual); primary completion 2023-05-25 (actual). Results posted on 2024-04-04.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 175 participants (enrolled count; ClinicalTrials.gov record NCT02489539, source copy `cardio:ctgov-nct02489539-2025-08-13`, retrieved 2026-11-18)
- Started: 2017-12-19 (actual) (ClinicalTrials.gov record NCT02489539, source copy `cardio:ctgov-nct02489539-2025-08-13`, retrieved 2026-11-18)
- Primary completion: 2023-05-25 (actual) (ClinicalTrials.gov record NCT02489539, source copy `cardio:ctgov-nct02489539-2025-08-13`, retrieved 2026-11-18)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT02489539, source copy `cardio:ctgov-nct02489539-2025-08-13`, retrieved 2026-11-18)
- Results first posted: 2024-04-04 (ClinicalTrials.gov record NCT02489539, source copy `cardio:ctgov-nct02489539-2025-08-13`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT02489539, source copy `cardio:ctgov-nct02489539-2025-08-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02489539-2025-08-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms
- Condition: Aortic Aneurysm, Abdominal
- Intervention (Device): GORE® EXCLUDER® Conformable AAA Endoprosthesis
- Lead sponsor: W.L.Gore & Associates
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Abdominal aortic aneurysm (`cardio:abdominal-aortic-aneurysm`)
- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: W.L.Gore & Associates (`cardio:org-w-l-gore-associates`)

## Provenance

Content hash: 9b75297fd72c6044f7519c357a79df956faa7996b903eeeb50ffec7917871466
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
